Teva Pharm sees lower than forecast 2015 revenue

TEL AVIV, Dec 11 (Reuters) - Teva Pharmaceutical Industries , the world's biggest generic drugmaker, forecast 2015 revenue below analysts' expectations and assumes its best-selling multiple sclerosis treatment will face competition in September.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.